-
Jupiter Neurosciences, Inc. to Present at Centri Capital Conference on April 14
-
Jupiter Neurosciences targets GLP-1 users with Nugevia supplement line
-
Jupiter Neurosciences Presenting at the 3rd Annual DealFlow Discovery Conference
-
DealFlow Discovery Conference Announces Initial Lineup of Presenting Companies Ahead of Next Week's Event
-
DealFlow Discovery Conference Announces Initial Lineup of Presenting Companies Ahead of Next Week's Event
-
DealFlow Discovery Conference Announces Initial Lineup of Presenting Companies Ahead of Next Week's Event
-
DealFlow Discovery Conference Announces Initial Lineup of Presenting Companies Ahead of Next Week's Event
-
Jupiter Neurosciences receives FDA clearance for Parkinson's trial
-
Jupiter Neurosciences to Participate in NobleCon21
-
Jupiter Neurosciences secures up to $20 million financing deal
-
Jupiter Neurosciences reports 9x bioavailability boost for resveratrol drug
-
Jupiter Neurosciences regains NASDAQ compliance after stock price recovery
-
Jupiter Neurosciences (JUNS) Showcases Nugevia PWR: Mitochondrial Optimization Supplement Designed to Boost Energy, Endurance, and Recovery
-
Jupiter Neurosciences (JUNS) Unveils Nugevia GLO
-
Jupiter Neurosciences (JUNS) Launches Nugevia
-
Jupiter Neurosciences (JUNS) Highlights Upcoming Milestones in Shareholder Letter
-
Alliance Entertainment and Jupiter Neurosciences Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
-
Jupiter Neurosciences (JUNS) and Aquanova AG Announce Strategic Collaboration to Develop Longevity and Healthspan Products
-
Jupiter Neurosciences (JUNS) Addresses Market Volatility
-
Jupiter Neurosciences (JUNS) Announces JOTROL Manufacturing Agreement with Catalent to Support Phase 2a Parkinson’s Trial
-
Jupiter Neurosciences (JUNS) Partners with Zina Biopharmaceuticals to Advance Phase 2a Parkinson’s Trial
-
Jupiter Neurosciences (JUNS) Announces Strategic Focus on NLRP3 Pathway in Future JOTROL Trials
-
Greenridge Capital Starts Jupiter Neurosciences (JUNS) at Buy
-
Jupiter Neurosciences (JUNS) Files for 2.75M Share IPO at $4-$5/sh

